

2023 RECAP

#RAREAdvocacySummit



Patient Advocate (46%)

Corporate/Industry (26%)

Caregiver (12%)

Patient (6%)

Scientist/Researcher (non-industry) (4%)

Government (1%)

We're dealing with rare diseases, but they all have common issues and common needs. We can try to fight barriers together and figure out how to move forward. - Joni L Rutter, PhD 3 5

User Experience

84%

of attendees felt more knowledgeable about patient advocacy and opportunities for patient advocates/organizations to engage.



88%
of attendees made
important connections
with others in the rare
disease community during
this event.

Your flock is in this room. You find your flock at these meetings by engaging and talking with other groups and realizing that there are common opportunities to work together. This isn't isolated to foundation groups. At the academic level, I collaborate with lots of institutions and other providers. In rare disease, everything you accomplish that's meaningful happens because of collaboration.

- Scott Demarest, MD

GLOBALGENES.ORG